148 related articles for article (PubMed ID: 12866577)
81. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
[TBL] [Abstract][Full Text] [Related]
82. Chromosome aberrations [dup(1q)] in endometrial cancer: Gene analysis of 54 surgical specimens in Turkey.
Sever E; Döğer E; Kumbasar S; Şık BA; Temur M; Yılmaz HT; Yılmaz Ö; Özbay PO; Yücesoy İ
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):357-62. PubMed ID: 27343315
[TBL] [Abstract][Full Text] [Related]
83. Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization.
Mark HF; Feldman D; Das S; Samy M; Sun CL; Mark S
Exp Mol Pathol; 1999 Oct; 67(2):109-17. PubMed ID: 10527762
[TBL] [Abstract][Full Text] [Related]
84. Concordance Between Immunohistochemistry (IHC) and Silver Situ Hybridization (SISH) in Endometrial Carcinoma Diagnosis: Using HER-2/neu.
Mohammed Elmahi O; Ali Waggiallah H
Pak J Biol Sci; 2020 Jan; 23(10):1332-1337. PubMed ID: 32981267
[TBL] [Abstract][Full Text] [Related]
85. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.
Walch A; Bink K; Hutzler P; Höfler H; Werner M
Hum Pathol; 2000 Oct; 31(10):1332-4. PubMed ID: 11070129
[No Abstract] [Full Text] [Related]
86. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer.
Cianciulli AM; Botti C; Coletta AM; Buglioni S; Marzano R; Benevolo M; Cione A; Mottolese M
Cancer Genet Cytogenet; 2002 Feb; 133(1):66-71. PubMed ID: 11890992
[TBL] [Abstract][Full Text] [Related]
87. High-level detection of gene amplification and chromosome aneuploidy in extracted nuclei from paraffin-embedded tissue of human cancer using FISH: a new approach for retrospective studies.
Rossi E; Ubiali A; Balzarini P; Cadei M; Alpi F; Grigolatoi PG
Eur J Histochem; 2005; 49(1):53-8. PubMed ID: 15823795
[TBL] [Abstract][Full Text] [Related]
88. Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer.
Kobyakov DS; Avdalyan AM; Bobrov IP; Bychkova EY; Lazarev AF; Lushnikova EL; Nepomnyashchikh LM
Bull Exp Biol Med; 2014 Oct; 157(6):789-93. PubMed ID: 25348568
[TBL] [Abstract][Full Text] [Related]
89. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
[TBL] [Abstract][Full Text] [Related]
90. [Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular carcinoma and their clinical significance].
Huang BJ; Zhu ZY; Liang QW; Fang Y
Zhonghua Bing Li Xue Za Zhi; 2003 Feb; 32(1):20-4. PubMed ID: 12760798
[TBL] [Abstract][Full Text] [Related]
91. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Muraca PJ; Ross JS
J Clin Oncol; 1998 Apr; 16(4):1302-9. PubMed ID: 9552030
[TBL] [Abstract][Full Text] [Related]
92. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
Pisani AL; Barbuto DA; Chen D; Ramos L; Lagasse LD; Karlan BY
Obstet Gynecol; 1995 May; 85(5 Pt 1):729-34. PubMed ID: 7724103
[TBL] [Abstract][Full Text] [Related]
93. Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in "thin" and "thick" tissue sections.
Kouvaras E; Papandreou CN; Daliani DD; Athanasiadis A; Koukoulis GK
Breast; 2012 Feb; 21(1):34-9. PubMed ID: 21855343
[TBL] [Abstract][Full Text] [Related]
94. Squamous cell carcinoma of the esophagus: evaluation of the status of epidermal growth factor receptors (EGFR and HER-2) by immunohistochemistry and in situ hybridization.
Delektorskaya VV; Chemeris GY; Zavalishina LE; Ryazantseva AA; Grigorchuk AY; Kononets PV; Davydov MI
Bull Exp Biol Med; 2010 Oct; 149(5):615-20. PubMed ID: 21165401
[TBL] [Abstract][Full Text] [Related]
95. New concepts in the diagnosis and prognosis of endometrial carcinoma.
Sasano H; Watanabe K; Ito K; Sato S; Yajima A
Pathol Annu; 1994; 29 ( Pt 2)():31-49. PubMed ID: 7936750
[TBL] [Abstract][Full Text] [Related]
96. HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
Xu M; Schwartz P; Rutherford T; Azodi M; Santin A; Silasi D; Martel M; Hui P
Histopathology; 2010 Jan; 56(2):269-73. PubMed ID: 20102407
[No Abstract] [Full Text] [Related]
97. Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma.
Backe J; Gassel AM; Krebs S; Müller T; Caffier H
Arch Gynecol Obstet; 1997; 259(4):189-95. PubMed ID: 9271838
[TBL] [Abstract][Full Text] [Related]
98. Expression of MIF and c-erbB-2 in endometrial cancer.
Xiao W; Dong X; Zhao H; Han S; Nie R; Zhang X; An R
Mol Med Rep; 2016 May; 13(5):3828-34. PubMed ID: 26985869
[TBL] [Abstract][Full Text] [Related]
99. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
Hirsch FR; Varella-Garcia M; Franklin WA; Veve R; Chen L; Helfrich B; Zeng C; Baron A; Bunn PA
Br J Cancer; 2002 May; 86(9):1449-56. PubMed ID: 11986780
[TBL] [Abstract][Full Text] [Related]
100. Amplification studies of MET and Cdk6 in a rat endometrial tumor model and their correlation to human type I endometrial carcinoma tumors.
Samuelson E; Nordlander C; Levan G; Behboudi A
Adv Exp Med Biol; 2008; 617():511-7. PubMed ID: 18497076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
